Valbiotis
Develops clinically proven, plant-based supplements for metabolic diseases.
ALVAL | PA
Overview
Corporate Details
- ISIN(s):
- FR0013254851
- LEI:
- 969500VP4JBJCF0MOP60
- Country:
- France
- Address:
- RUE PAUL VATINE, 17180 PERIGNY
- Website:
- https://www.valbiotis.com/en/
- Sector:
- Manufacturing
- Industry:
- Manufacture of other food products
Description
Valbiotis is a research and development company that develops and commercializes plant-based dietary supplements for the prevention and management of metabolic diseases. The company's portfolio is centered on its patented "TOTUM" line of active substances, which undergo rigorous clinical trials to validate their efficacy. Key products include TOTUM•63 for reducing blood glucose in prediabetic individuals, TOTUM•448 for cardio-liver health, and TOTUM•854 for managing blood pressure. Valbiotis provides scientifically proven, natural, non-drug solutions and is transitioning from a research-focused model to a commercial-stage enterprise.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2024-01-29 17:40 |
Valbiotis publie son calendrier financier de l’exercice 2024
|
French | 487.3 KB | ||
| 2024-01-16 17:40 |
Valbiotis sets out its commercial and clinical roadmap for 2024
|
English | 533.9 KB | ||
| 2024-01-16 17:40 |
Valbiotis précise sa feuille de route commerciale et clinique pour l’année 2024
|
French | 543.8 KB | ||
| 2024-01-09 17:40 |
Valbiotis : Information mensuelle relative au nombre total de droits de vote e…
|
French | 105.3 KB | ||
| 2023-12-22 07:35 |
Valbiotis announces the success of its €15 M capital increase
|
English | 383.3 KB | ||
| 2023-12-22 07:35 |
Valbiotis annonce le succès de son augmentation de capital de 15 millions d'eu…
|
French | 382.3 KB | ||
| 2023-12-11 21:03 |
Valbiotis announces the launch of a capital increase
|
English | 494.1 KB | ||
| 2023-12-11 21:03 |
Valbiotis annonce le lancement d’une augmentation de capital
|
French | 1.4 MB | ||
| 2023-12-11 21:00 |
Valbiotis annonce le lancement d’une augmentation de capital avec suppression d…
|
French | 1.4 MB | ||
| 2023-12-11 21:00 |
Valbiotis announces the launch of a capital increase with the cancellation of p…
|
English | 494.1 KB | ||
| 2023-12-11 20:23 |
Valbiotis announces the availability of an amendment to the Universal Registrat…
|
English | 480.8 KB | ||
| 2023-12-11 20:23 |
Valbiotis informe de la mise à disposition d’un amendement au Document d’enregi…
|
French | 483.4 KB | ||
| 2023-12-11 20:02 |
Valbiotis announces that it has received Food and Drug Administration (FDA) app…
|
English | 495.6 KB | ||
| 2023-12-11 20:02 |
Valbiotis annonce avoir reçu l’acceptation de la Food and Drug Administration …
|
French | 499.0 KB | ||
| 2023-12-11 20:00 |
Valbiotis annonce avoir reçu l’acceptation de la Food and Drug Administration (…
|
French | 499.0 KB |
Automate Your Workflow. Get a real-time feed of all Valbiotis filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Valbiotis
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Valbiotis via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2023-01-17 | N/A | Other | Other | 10,400 | 46,072.00 EUR |
Peer Companies
